Table 3a. Association between patient characteristics and survival in Stage I & II NSCLC.
| Univariate HR (95% CI) |
Univariate P-Value |
Multivariate HR (95% CI) |
Multivariate P-Value |
|
|---|---|---|---|---|
| Age | ||||
| < 65 | Reference | <0.001 | Reference | 0.004 |
| ≥ 65 | 1.86 (1.31-2.63) | 2.22 (1.29-3.82) | ||
| Gender | ||||
| Male | Reference | <0.001 | Reference | <0.001 |
| Female | 0.57 (0.41-0.79) | 0.53 (0.38-0.74) | ||
| Race | ||||
| White, non-Hispanic | Reference | 0.77 | Reference | 0.87 |
| Other | 1.05 (0.74-1.51) | 0.97 (0.65-1.44) | ||
| Insurance | ||||
| Private | Reference | 0.001 | Reference | 0.04 |
| Medicare | 2.07 (1.37-3.14) | 1.27 (0.72-2.22) | ||
| Indigent | 2.20 (1.33-3.62) | 1.98 (1.16-3.37) | ||
| Stage | ||||
| Stage I | Reference | 0.06 | Reference | 0.04 |
| Stage II | 1.44 (0.98-2.11) | 1.52 (1.02-2.29) | ||
| Histology | ||||
| Adenocarcinoma | Reference | 0.06 | Reference | 0.06 |
| Squamous Cell | 1.27 (0.88-1.84) | 1.09 (0.75-1.58) | ||
| Other * | 1.74 (1.07-2.83) | 1.83 (1.12-2.99) | ||
| Treatment # | ||||
| “ Standard ” | Reference | <0.001 | Reference | <0.001 |
| Other | 2.60 (1.73-3.93) | 2.13 (1.37-3.31) |
HR>1: shorter survival
*
Includes patients with large cell, adenosquamous or unspecified
#
For Treatment, Standard=Surgery. Other =No Surgery